Exemestane bone mineral density

In 70 postmenopausal women with completely resected breast cancers who were disease-free after taking tamoxifen for 2—3 years, a switch to exemestane resulted in increases in serum bone alkaline phosphatase and the carboxy-terminal telopeptide of type I collagen and a fall in parathormone bone mineral density worsened (28). 

In 147 postmenopausal women with early breast cancer who took exemestane in a placebo-controlled study, the mean annual rate of bone mineral density loss was 2.17% versus 1.84% in the lumbar spine and 2.72% versus 1.48% in the femoral neck with exemestane versus placebo. The mean changes in T score after 2 years were -0.21 versus —0.11 in the hip and —0.30 versus -0.21 in the lumbar spine (14). 

Lpnning PE, Geisler J, Krag LE, Erikstein B, Bremnes Y, Hagen AI, Schlichting E, Lien EA, Ofjord ES, Paolini J, Polli A, Massimini G. Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer. J Clin Oncol 2005 23(22) 5126-37. 

Coleman, R.E., Banks, L.M., Girgis, S.I., Kilbum, L.S., Vrdoljak, E Fox, J., Cawthom, S.J., Patel, A., Snowdon, C.F., Hall, E., Bliss, J.M. and Coombes, R.C. (2007) Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES) a randomised controlled study. The Lancet Oncology, 8, 119-127. 

Musculoskeletal Changes in bone mineral density from baseline to 24 months have been studied in 167 women taking either exemestane 25 mg/day or tamoxifen 20 mg/day [50 ]. There was more bone loss at both the spine and the hip with exemestane during the first 12 months, but by 2 years the differences were less apparent and the bone loss with exemestane had slowed, the difference being significant only at the hip. 

Jones S, Stokoe C, Sborov M, Braun M, Ethirajan S, Kutteh L, Pippen J, Patel M, Paul D, Blum JL, Holmes FA, M5fron MC, Cantrell J, Hartung NL, Look RM, Di Salle E, Davis JC, Degbodu D, Asmar L. The effect of tamoxifen or exemestane on bone mineral density during the first 2 years of adjuvant treatment of postmenopausal women with early breast cancer. Clin Breast Cancer 2008 8(6) 527-32. 

---

See also in sourсe #XX -- [ ]

---